We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GVTD:BSEGE Vernova T&D India Limited Analysis

Data as of 2026-03-14 - not real-time

₹3,603.55

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock is currently trading just below its 20‑day simple moving average while remaining above the 50‑day and 200‑day averages, indicating a short‑term pullback within a longer‑term uptrend. Technical signals are mixed: the RSI sits near the midpoint, the MACD histogram is negative and the MACD line trails its signal, and volume has been trending down, all of which temper the bullish bias.
Fundamentally, the company is delivering strong top‑line growth of nearly 60% YoY, solid profitability with gross margins around 37% and an impressive ROE above 30%, and robust cash generation that comfortably covers its modest debt load. However, valuation metrics are extreme – a forward P/E near 132× and a price‑to‑book ratio exceeding 60× – and the market price sits well above analyst target levels, suggesting the stock is significantly overvalued at present. With no dividend policy and a modest beta indicating limited market‑wide volatility, the primary risks stem from high price volatility, decreasing liquidity, and sector‑specific regulatory headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below 20‑day SMA indicating short‑term weakness
  • Bearish MACD histogram and decreasing volume
  • Neutral RSI suggesting limited upside momentum

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustained revenue growth and strong operating margins
  • Robust cash flow covering debt and supporting future projects
  • Bullish long‑term trend despite short‑term technical pullback

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic position in India's expanding power transmission and digital grid market
  • High ROE and solid balance sheet enabling continued investment
  • Analyst consensus buy despite current overvaluation, indicating belief in long‑run upside

Key Metrics & Analysis

Financial Health

Revenue Growth58.80%
Profit Margin10.34%
P/E Ratio132.0
ROE31.44%
ROA9.45%
Debt/Equity2.77
P/B Ratio67.0
Op. Cash Flow₹7.9B
Free Cash Flow₹3.0B

Technical Analysis

TrendBullish
RSI48.8
Support₹3,487.55
Resistance₹3,998.00
MA 20₹3,734.13
MA 50₹3,344.98
MA 200₹2,899.74
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Target Price₹2,096.20
Upside/Downside-41.83%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.39
Volatility38.64%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.